Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?

被引：0
作者：
Felicia Cosman
David W. Dempster
机构：
[1] College of Physicians and Surgeons of Columbia University,Department of Medicine
[2] College of Physicians and Surgeons of Columbia University,Endocrinology
[3] College of Physicians and Surgeons of Columbia University,Department of Pathology and Cell Biology
来源：
Current Osteoporosis Reports | 2021年 / 19卷
关键词：
Postmenopausal osteoporosis; Teriparatide; Abaloparatide; Romosozumab; Treatment sequence; Anabolic;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：189 / 205
页数：16
相关论文
共 887 条
[1]  
Cosman F(2020)Anabolic therapy and optimal treatment sequences for patients with osteoporosis at high risk for fracture Endocr Pract 26 777-786
[2]  
Neer RM(2001)Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434-1441
[3]  
Arnaud CD(2016)Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial JAMA. 316 722-733
[4]  
Zanchetta JR(2016)Romosozumab treatment in postmenopausal women with osteoporosis N Engl J Med 375 1532-1543
[5]  
Prince R(2018)Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial Lancet 391 230-240
[6]  
Gaich GA(2017)Romosozumab or alendronate for fracture prevention in women with osteoporosis N Engl J Med 377 1417-1427
[7]  
Reginster JY(2020)Effect of abaloparatide vs alendronate on fracture risk reduction in postmenopausal women with osteoporosis J Clin Endocrinol Metab 105 938-943
[8]  
Hodsman AB(2019)Risk of subsequent fracture after prior fracture among older women Osteoporos Int 30 79-92
[9]  
Eriksen EF(2018)Characteristics of recurrent fractures Osteoporos Int 29 1747-1757
[10]  
Ish-Shalom S(2017)Imminent fracture risk Osteoporos Int 28 1765-1769
12345678910